Replies to post #286 on Vascular Biogenics Ltd (VBLT)

[davidal66]

I would like to compare the low dose cohort to the therapeutic cohort in terms of survival, progression free survival, ect... but this will have to wait a few weeks till ASCO. As to the expected overall survival in patients who fail platinum and avastin, I believe the numbers are pretty bleak. Am I reading these numbers right? or is the dataset looking very encouraging.

[davidal66]

??????????????VB-111 in Platinum-Resistant Ovarian Cancer Phase 1/2 Clinical Trial
Three dose levels: Dose Level 1
Dose Level 2 N=3
Dose Level 3 N=4
Expansion N=6
Results
N=3
3x1012 VPs + 40mg paclitaxel
3x1012 VPs + 80mg paclitaxel
1x1013 VPs + 80mg paclitaxel
1x1013 VPs + 80mg paclitaxel
VB-111 Group
Patients Status
mOS
Low dose High Dose
4/4 died
8/12 patients are still alive
6 months

This is data from last year's SNO presentation on VB-111 in November. the 6 months on the bottom is the overall survival on the number on the 4 patients who received low dose VB-111 where 4/4 died at the time of SNO. The 8/12 number still alive was the expansion cohort at the therapeutic dose of VB-111 at the time of SNO...7 additional patients have since been added to the 12, yielding the 19 patients referred to in today's abstract. Again, I'm not sure how to parse/extrapolate the mean survival number of 19.9 months except to say it appears the magnitude of effect of VB-111 is as robust in the ovarian cancer trial as the rGBM phase II trial. A final thought: note that the ovarian trial contained by definition not just platinum resistant patients but also many patient who failed avastin as well. Yes, it's early and this is a small trial, but this sounds like a fantastic response.